Compare FOSL & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOSL | LRMR |
|---|---|---|
| Founded | 1984 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.7M | 455.8M |
| IPO Year | 1994 | 2014 |
| Metric | FOSL | LRMR |
|---|---|---|
| Price | $7.16 | $2.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $9.25 | ★ $14.40 |
| AVG Volume (30 Days) | 733.7K | ★ 1.3M |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.26 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,004,406,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $2.53 |
| 52 Week High | $7.33 | $6.42 |
| Indicator | FOSL | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 69.18 | 16.38 |
| Support Level | $3.74 | N/A |
| Resistance Level | $7.33 | $4.19 |
| Average True Range (ATR) | 0.38 | 0.20 |
| MACD | 0.05 | -0.08 |
| Stochastic Oscillator | 88.98 | 0.29 |
Fossil Group Inc is a design, innovation, and distribution company in consumer fashion accessories, offering products such as watches, jewelry, handbags, small leather goods, belts, and sunglasses. It designs, develops, markets, and distributes products under its owned brands FOSSIL, SKAGEN, MICHELE, RELIC, and ZODIAC. It operates through Americas, Europe, and Asia segments, each including sales to wholesale and distributor customers, as well as Company-owned retail stores and e-commerce activities based on the location of the selling entity. The Americas segment contributes the majority of revenue and includes sales across Canada, Latin America, and the United States, while the Europe and Asia segments cover their respective regions. Each segment provides similar products and services.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.